Weightloss Drug

Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Eli Lilly Releases Cheaper Zepbound Vials Priced Up To 50% Lower To Boost Access, Supply For Its Popular Weight Loss Drug
Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices

Weightloss Drug Recent News

Eli Lilly's Famed Obesity/Diabetes Treatment Tirzepatide Shows Potential To Cut Risk Of Developing Diabetes, Sustained Weight Loss Over 3 Years
Eli Lilly's SURMOUNT-1 three-year study reveals tirzepatide's effectiveness in reducing type 2 diabetes risk and achieving significant long-term weight loss in adults with pre-diabetes and obesity.
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while Roche's cautious approach reflects past market setbacks.
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs as supply improves. The move has sparked tension, with providers arguing that brand-name medications remain difficult to obtain.
Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the drug called petrelintide.
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Compounding weight loss drugs, which are similar to brand-name medications such as Ozempic and Mounjaro, will be banned in Australia.
The Ozempic Diet: Nestle Launches $5 Pizza For Weight Loss Drug Users
Nestlé SA launches Vital Pursuit, a new food line tailored for GLP-1 weight loss medication users, featuring protein, fiber, and essential nutrients. Available Q4 nationwide.
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1 agonists are poised to drive a $2 billion market by 2030.
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease using Lilly branding. Corrective measures include compliance with federal law for tirzepatide products.
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could impact millions, tackling accessibility challenges amidst rising costs.
Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects 20% Revenue Increase In 2024
This surge is attributed to the popularity of Lilly's new diabetes drug, Mounjaro, and its anti-obesity medication, Zepbound.
Berberine, Dubbed 'Nature's Ozempic,' Rises In Popularity — But Mind The Gastrointestinal Side Effect